Hinge Health HNGE 深 沪
交易中 10-02 11:06:23 美东时间
97.96
+0.020
+0.02%
华盛通- 最 高99.7296
- 今 开98.84
- 成交量 20.80万股
- 最 低 97.33
- 昨 收 97.94
- 总市值 79.05亿
- 52周最高 99.7296
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 30.08
- 委 比 89.74%
- 总股本 8069.44万
- 历史最高 99.7296
- 量 比 0.70
- 振 幅 2.45%
- 历史最低 30.08
- 每 手 1
- 风险率 19.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BNP Paribas raised the price target for Carmax Inc (NYSE:KMX) from $33 to $48. BNP Paribas analyst Chris Botti...
09-30 20:22
Needham Maintains Buy on Hinge Health, Raises Price Target to $115
Needham analyst Ryan MacDonald maintains Hinge Health (NYSE:HNGE) with a Buy and raises the price target from $97 to $115.
09-30 18:10
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Baird Maintains Neutral on Hinge Health, Raises Price Target to $90
Baird analyst Vikram Kesavabhotla maintains Hinge Health (NYSE:HNGE) with a Neutral and raises the price target from $85 to $90.
09-22 20:59
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Stifel Maintains Buy on Hinge Health, Raises Price Target to $115
Stifel analyst David Grossman maintains Hinge Health (NYSE:HNGE) with a Buy and raises the price target from $96 to $115.
09-09 01:44
Jim Cramer Recommends Buying This Health Care Stock: ‘What A Quarter They Had’
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Hinge Health, Inc. (NYSE:HNGE) is a buy. “What a quarter they had,” he added. Hinge Health, on Aug. 4, posted better-than-expected quarterly sales and raised its FY2026 sales guidance. The company also announced plans to acquire Cylinder Health ...
08-12 20:40
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
财报速睇 | Hinge Health 2026财年Q2营收2.13亿美元，同比增长53.2%；归母净利润0.43亿美元，扭亏为盈
华盛资讯8月7日讯，Hinge Health公布2026财年Q2业绩，公司Q2营收2.13亿美元，同比增长53.2%，归母净利润0.43亿美元，扭亏为盈。
08-07 09:47
